Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

Table 8

Management of anti-EGFR-associated rash and common terminology criteria for adverse events v3.0 (CTCAE), National Cancer Institute.

CTC Grade	Rash	Management
1	Macular or papular eruption or erythema Asymptomatic	Topical antibiotic agents (metronidazole, erythromycin, and clindamycin lotion) Corticosteroid cream if an extensive inflammatory component exists
2	Macular or papular eruption or erythema Symptomatic covering <50% of body	Anti-inflammatory oral antibiotics (minocycline or doxycycline) Corticosteroid cream if an extensive inflammatory component exists
3	Macular or papular eruption or erythema Symptomatic covering >50% of body	Anti-inflammatory oral antibiotics (minocycline or doxycycline) Oral corticosteroids EGFR therapy should be held until the acute inflammatory phase has resolved
4	Generalized exfoliative, ulcerative, or bullouis dermatitis	Anti-inflammatory oral antibiotics (minocycline or doxycycline) Oral corticosteroids (Medrol-dose pack) EGFR therapy should be held until the acute inflammatory phase has resolved